Surgical player agrees acquisition of biomaterials firm

Surgical and wound care company Advanced Medical Solutions (AMS) has acquired surgical biomaterial technologies player Biomatlante for €8 million.

There is potential for another €0.3 million to be paid over the next two years subject to certain new product approval milestones being met.

Chris Meredith, CEO of AMS, said: “This acquisition is in line with our strategy to acquire technologies that are complementary to our surgical portfolio and allow us to leverage our global routes to market. The acquisition grants AMS access to multiple new markets, including the synthetic bone substitutes market which is estimated at $0.5 billion. We are excited to welcome the Biomatlante team to AMS and look forward to working together with them to accelerate the commercial success internationally and to continue to develop the Biomatlante technology in a wide range of potential applications and indications.”

The acquisition aims to strengthen AMS’s product portfolio, R&D pipeline, and market access. It provides the Group with a range of surgical products and an R&D pipeline of complementary biosurgical technologies.

Biomatlante’s biosurgical products, which are sold mainly in Europe, generated sales of more than €4 million in 2018. AMS aims to increase sales in other jurisdictions through its global commercial infrastructure, as well as leveraging Biomatlante’s established presence in France for the Group’s existing surgical product portfolio.

The R&D pipeline and platform technologies which AMS acquired will broaden the Group’s biosurgical technology offering while also offering synergies across the sales, marketing, regulatory, operational divisions and R&D.

Biomatlante has a platform used in orthopaedic, spinal, dental and sports surgery and a development pipeline of next-generation products. The company’s commercialised products include synthetic bone substitutes, collagen membranes and bioabsorbable screws.

Biomatlante is ISO 13485 and MDSAP accredited with extensive clinical evidence and is well prepared for the new European Medical Device Regulation.

Chantal Gobin-Daculsi, co-founder and president of Biomatlante said: "This is an important strategic step for Biomatlante and we are excited to become part of the AMS group. AMS is a high-quality global company with the scale, expertise and track record of realising the value of scientific innovation and rapidly growing the sales of marketed products. Our product portfolios, product pipelines and geographic footprints are highly complementary, and, as part of the AMS family, the know-how of our team can be fully realised, allowing our pipeline of synthetic bone substitutes to be commercialised on a global scale.”